BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23456762)

  • 1. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
    Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
    Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma.
    Zivanovic O; Jacks LM; Iasonos A; Leitao MM; Soslow RA; Veras E; Chi DS; Abu-Rustum NR; Barakat RR; Brennan MF; Hensley ML
    Cancer; 2012 Feb; 118(3):660-9. PubMed ID: 21751199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram for predicting overall survival in patients with uterine leiomyosarcoma: a SEER population-based study.
    Lu YJ; Wang H; Fang LY; Wang WJ; Song W; Wang Y; Huang YQ; Din ZL
    Future Oncol; 2020 Apr; 16(10):573-584. PubMed ID: 32141309
    [No Abstract]   [Full Text] [Related]  

  • 4. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and Validation of Nomograms for Predicting the Prognosis of Uterine Leiomyosarcoma: A Population-Based Study.
    Meng Y; Yang Y; Zhang Y; Li X
    Med Sci Monit; 2020 Apr; 26():e922739. PubMed ID: 32270788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine leiomyosarcoma: an updated series.
    Rauh-Hain JA; Oduyebo T; Diver EJ; Guseh SH; George S; Muto MG; del Carmen MG
    Int J Gynecol Cancer; 2013 Jul; 23(6):1036-43. PubMed ID: 23714705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
    Raut CP; Nucci MR; Wang Q; Manola J; Bertagnolli MM; Demetri GD; Morgan JA; Muto MG; Fletcher CD; George S
    Eur J Cancer; 2009 Nov; 45(16):2818-24. PubMed ID: 19647426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
    Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
    Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
    Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
    BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
    Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
    Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
    Pedra Nobre S; Hensley ML; So M; Zhou QC; Iasonos A; Leitao MM; Ducie J; Chiang S; Mueller JJ; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2021 Jan; 160(1):99-105. PubMed ID: 33158511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study.
    Bekos C; Grimm C; Brodowicz T; Petru E; Hefler L; Reimer D; Koch H; Reinthaller A; Polterauer S; Polterauer M
    Sci Rep; 2017 Nov; 7(1):14474. PubMed ID: 29101329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study.
    Bizzarri N; Ghirardi V; Di Fiore GLM; De Iaco P; Gadducci A; Casarin J; Perrone AM; Pasciuto T; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2019 Sep; 29(7):1134-1140. PubMed ID: 31420411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study.
    Garg G; Shah JP; Liu JR; Bryant CS; Kumar S; Munkarah A; Morris RT
    Int J Gynecol Cancer; 2010 Oct; 20(7):1201-6. PubMed ID: 20940535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
    Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
    George S; Barysauskas C; Serrano C; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Demetri GD; Muto MG
    Cancer; 2014 Oct; 120(20):3154-8. PubMed ID: 24923260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive lymphadenectomy and survival prediction in uterine serous cancer patients after surgery: A population-based analysis.
    Li H; Xie X; Liu Y; Huang X; Lin H; Li J; Lin Z
    Eur J Surg Oncol; 2020 Jul; 46(7):1339-1346. PubMed ID: 32402510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of a multi-institutional retroperitoneal sarcoma nomogram.
    Raut CP; Miceli R; Strauss DC; Swallow CJ; Hohenberger P; van Coevorden F; Rutkowski P; Fiore M; Callegaro D; Casali PG; Haas RL; Hayes AJ; Honore C; Cannell AJ; Jakob J; Szacht M; Fairweather M; Pollock RE; Bonvalot S; Gronchi A
    Cancer; 2016 May; 122(9):1417-24. PubMed ID: 26916507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma.
    Schwameis R; Grimm C; Petru E; Natter C; Staudigl C; Lamm W; Koelbl H; Krainer M; Brodowicz T; Reinthaller A; Polterauer S
    PLoS One; 2015; 10(8):e0133838. PubMed ID: 26248232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.